IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 2, Issue 3 (2021)
J Clinic Care Skill 2021, 2(3): 129-138 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Daneshyar Z, Rahimi N. A Review on Laboratory Findings of Patients with COVID-19 Infection. J Clinic Care Skill 2021; 2 (3) :129-138
URL: http://jccs.yums.ac.ir/article-1-110-en.html
URL: http://jccs.yums.ac.ir/article-1-110-en.html
Z. Daneshyar *1, N. Rahimi2
1- Clinical Research Development Unit, Imamsajad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran , shadi_med79@yahoo.com
2- Clinical Research Development Unit, Imamsajad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran
2- Clinical Research Development Unit, Imamsajad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran
Abstract: (1235 Views)
Aims: This study aimed to evaluate the diagnostic and laboratory findings of infections caused by acute coronavirus syndrome 2 (SARS-CoV-2).
Information & Methods: This systematic review was carried out using research in Google Scholar, international databases such as Pubmed, Wiley, and Sciencedirect, and Iranian databases including SID and Magiran by the keywords SARS-CoV-2, COVID-19 diagnostic methods, PCR, COVID-19, and hematology parameters. Finally, 93 articles were selected and reviewed.
Findings: Reverse transcription-polymerase chain reaction and molecular test methods are the method of choice to diagnose the cause of SARS-CoV-2 infection. Serological testing is not yet sensitive enough and specific for diagnosis. The clinical spectrum of the infection is wide, including asymptomatic infection, relatively mild upper respiratory tract disease, and severe viral pneumonia with respiratory failure and even death. The incidence of lymphopenia, thrombocytopenia, and coagulation disorders occur in severe cases of the disease and are associated with a poor prognosis. An increase of D-dimer levels in severe cases of the disease suggests anticoagulant therapy. In severe disease, laboratory tests show changes in the immune system with overstimulation of the cytokine storm. In addition, biomarkers of specific organs indicate heart, kidney, and liver dysfunction in many patients.
Conclusion: Although virus detection by reverse transcription-polymerase chain reaction is the gold standard, if the test is negative, the definitive diagnosis of COVID-19 should be based on clinical data; other tests for complications of the disease are also important.
Information & Methods: This systematic review was carried out using research in Google Scholar, international databases such as Pubmed, Wiley, and Sciencedirect, and Iranian databases including SID and Magiran by the keywords SARS-CoV-2, COVID-19 diagnostic methods, PCR, COVID-19, and hematology parameters. Finally, 93 articles were selected and reviewed.
Findings: Reverse transcription-polymerase chain reaction and molecular test methods are the method of choice to diagnose the cause of SARS-CoV-2 infection. Serological testing is not yet sensitive enough and specific for diagnosis. The clinical spectrum of the infection is wide, including asymptomatic infection, relatively mild upper respiratory tract disease, and severe viral pneumonia with respiratory failure and even death. The incidence of lymphopenia, thrombocytopenia, and coagulation disorders occur in severe cases of the disease and are associated with a poor prognosis. An increase of D-dimer levels in severe cases of the disease suggests anticoagulant therapy. In severe disease, laboratory tests show changes in the immune system with overstimulation of the cytokine storm. In addition, biomarkers of specific organs indicate heart, kidney, and liver dysfunction in many patients.
Conclusion: Although virus detection by reverse transcription-polymerase chain reaction is the gold standard, if the test is negative, the definitive diagnosis of COVID-19 should be based on clinical data; other tests for complications of the disease are also important.
Article Type: Original Research |
Subject:
Special
Received: 2021/06/7 | Accepted: 2021/09/4 | Published: 2021/09/12
Received: 2021/06/7 | Accepted: 2021/09/4 | Published: 2021/09/12
References
1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;588(7836):6. [DOI:10.1038/s41586-020-2951-z] [PMID]
2. Wang Z, Xu X. ScRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, leydig and sertoli cells. Cells. 2020;9(4):920. [DOI:10.3390/cells9040920] [PMID] [PMCID]
3. Clarke JM, Majeed A, Beaney T. Measuring the impact of COVID-19. BMJ. 2021;373:1239. [DOI:10.1136/bmj.n1239] [PMID]
4. Chan JFW, To KKW, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: Lessons from bats and birds. Trends Microbiol. 2013;21(10):544-55. [DOI:10.1016/j.tim.2013.05.005] [PMID] [PMCID]
5. He J, Tao H, Yan Y, Huang SY, Xiao Y. Molecular mechanism of evolution and human infection with SARS-CoV-2. Viruses. 2020;12(4):428. [DOI:10.3390/v12040428] [PMID] [PMCID]
6. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect Dis. 2020;20(5):565-74. [DOI:10.1016/S1473-3099(20)30196-1]
7. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) 297 based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948. [DOI:10.1016/j.ijantimicag.2020.105948] [PMID] [PMCID]
8. Boccia S, Ricciardi W, Ioannidis JPA. What other countries can learn from italy during the COVID-19 pandemic. JAMA Intern Med. 2020;180(7):927-8. [DOI:10.1001/jamainternmed.2020.1447] [PMID]
9. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-12. [DOI:10.1016/j.jmii.2020.02.012] [PMID] [PMCID]
10. Worl health organization. Water, sanitation, hygiene, and waste management for the COVID-19 virus: Interim guidance [Internet]. Geneva: World Health Organization; 2020 [cited 2020 April 23]. Available from: [link]
11. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406-7. [DOI:10.1001/jama.2020.2565] [PMID] [PMCID]
12. Wang P, Lu J, Jin Y, Zhu M, Wang L, Chen S. Epidemiological characteristics of 1212 COVID-19 patients in Henan, China. MedRxiv. 2020 Feb:1-11. [DOI:10.1101/2020.02.21.20026112]
13. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ. 2020;368:606. [DOI:10.1136/bmj.m606] [PMID] [PMCID]
14. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343-60. [DOI:10.1631/jzus.B2000083] [PMID] [PMCID]
15. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun. 2020;88:945-6. [DOI:10.1016/j.bbi.2020.04.017] [PMID] [PMCID]
16. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): Encephalopathy. Cureus. 2020;12(3):7352. [DOI:10.7759/cureus.7352] [PMID] [PMCID]
17. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. [DOI:10.1056/NEJMoa2001017] [PMID] [PMCID]
18. World health organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) [Internet]. Geneva: World Health Organization; 2020 [cited: Unknown]. Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19). [link]
19. World health organization. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19): Interim guidance [Internet]. Geneva: World Health Organization [link]
20. 2020 [cited 2020 Feb 12]. Available from: https://www.who.int/publications/i/item/WHO-WPE-GIH-2021.1. [link]
21. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386-9. [DOI:10.1080/22221751.2020.1729071] [PMID] [PMCID]
22. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese Med J. 2020;133(9):1039-43. [DOI:10.1097/CM9.0000000000000774] [PMID] [PMCID]
23. Centers for disease control and preventation. Discontinuation of transmission-based precautions and disposition of patients with SARS-CoV-2 infection in healthcare settings [Internet]. Atlanta: Centers for Disease Control and Preventation; 2021 [cited: Unknown]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html. [link]
24. Centers for disease control and preventation. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing [Internet]. Atlanta: Centers for Disease Control and Preventation; 2021[cited: Unknown]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html. [link]
25. Centers for disease control and preventation. Specimen collection guidelines [Internet]. Atlanta: Centers for Disease Control and Preventation; 2021 [cited: Unknown]. Available from: Not Found. [link]
26. China CDC weekly. Technical guidelines for COVID-19 laboratory testing [Internet]. Beijing: China CDC Weekly; 2020 [cited: Unknown]. Available from: http://weekly.chinacdc.cn/en/article/id/0f6dc581-08f4-4828-97f0-9cc805969bbb. [link]
27. Kim C, Ahmed JA, Eidex RB, Nyoka R, Waiboci LW, Erdman D, et al. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. Plos One. 2011;6(6):21610. [DOI:10.1371/journal.pone.0021610] [PMID] [PMCID]
28. Ek P, Bottiger B, Dahlman D, Hansen KB, Nyman M, Nilsson AC. A combination of naso-and oropharyngeal swabs improves the diagnostic yield of respiratory viruses in adult emergency department patients. Infect Dis. 2019;51(4):241-8. [DOI:10.1080/23744235.2018.1546055] [PMID]
29. Spencer S, Thompson MG, Flannery B, Fry A. Comparison of respiratory specimen collection methods for detection of influenza virus infection by reverse transcription-PCR: A literature review. J Clin Microbiol. 2019;57(9):19-27. [DOI:10.1128/JCM.00027-19] [PMID] [PMCID]
30. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: Pitfalls and potential. Biotechniques. 1999;26(1):112-22. [DOI:10.2144/99261rv01] [PMID]
31. Kageyama T, Kojima S, Shinohara M, Uchida K, Fukushi S, Hoshino FB, et al. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J Clin Microbiol. 2003;41(4):1548-57. [DOI:10.1128/JCM.41.4.1548-1557.2003] [PMID] [PMCID]
32. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques. 2005;39(1):75-85. [DOI:10.2144/05391RV01] [PMID]
33. Bustin SA. A-Z of quantitative PCR. La Jolla: International University Line; 2004. [link]
34. Centers for disease control and preventation. Research use only 2019-novel coronavirus (2019-nCoV) real-time RT-PCR primers and probes [Internet]. Atlanta: Centers for Disease Control and Prevention; 2020 [cited: Unknown]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html. [link]
35. FDA. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel [Internet]. Silver Spring: FDA; 2020 [cited: Unknown]. Available from: https://www.fda.gov/media/134922/. [link]
36. American accociation for clinical chemistry. Multiple coronavirus tests receive regulatory approvals worldwide [Internet]. Washington: American Accociation for Clinical Chemistry; 2020 [cited: Unknown]. https://www.aacc.org/cln/articles/2020/april/multiple-coronavirus-tests-receive-regulatory-approvals-worldwide. [link]
37. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronaviruse (2019-nCoV) by real-time RT-PCR. Eur Surveill. 2020;25(3):2000045. [DOI:10.2807/1560-7917.ES.2020.25.3.2000045]
38. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem. 2020;66(4):549-55. [DOI:10.1093/clinchem/hvaa029] [PMID] [PMCID]
39. Shariff M, Soon S, Lee KL, Tan LT. Practical problems with PCR detection in Asia: The importance of standardization [Internet]. FAO; 2000 [Cited: Unknown]. Available from: http://www.fao.org/3/X4946E/x4946e0d.htm. [link]
40. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-8. [DOI:10.1016/j.jpha.2020.03.001] [PMID] [PMCID]
41. Lv H, Wu NC, Tsang OTY, Yuan M, Perera RA, Leung WS, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31(9):107725. [DOI:10.1016/j.celrep.2020.107725] [PMCID]
42. Fan BE. Hematologic parameters in patients with COVID‐19 infection: A reply. Am J Hematol. 2020;95(8):215. [DOI:10.1002/ajh.25847] [PMCID]
43. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. [DOI:10.1056/NEJMoa2002032] [PMID] [PMCID]
44. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8. [DOI:10.1093/cid/ciaa248] [PMID] [PMCID]
45. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020;58(7):1063-9. [DOI:10.1515/cclm-2020-0240] [PMID]
46. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5]
47. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] [PMCID]
48. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. [DOI:10.1001/jamainternmed.2020.0994] [PMID] [PMCID]
49. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-94. [DOI:10.1001/jama.2020.3204] [PMID] [PMCID]
50. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020;58(7):1135-8. [DOI:10.1515/cclm-2020-0272] [PMID]
51. Rahimzadeh G, Ekrami Noghabi M, Kadkhodaei Elyaderani F, Navaeifar MR, Enayati AA, Manafi Anari A, et al. COVID-19 infection in Iranian children: A case series of 9 patients. J Pediatr Rev. 2020;8(1):139-44. [DOI:10.32598/jpr.8.2.139]
52. Faria SS, Fernandes Jr PC, Silva MJB, Lima VC, Fontes W, Freitas-Junior R, et al. The neutrophil-to-lymphocyte ratio: A narrative review. Ecancermedicalscience. 2016;10:702. [DOI:10.3332/ecancer.2016.702] [PMID] [PMCID]
53. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):6-12. [DOI:10.1016/j.jinf.2020.04.002] [PMID] [PMCID]
54. Mitra A, Dwyre DM, Schivo M, Thompson III GR, Cohen SH, Ku N, et al. Leukoerythroblastic reaction in a patient with COVID‐19 infection. Am J Hematol. 202095(8):999-1000. [DOI:10.1002/ajh.25793] [PMID] [PMCID]
55. Rezaei M, Marjani M, Mahmoudi S, Mortaz E, Mansouri D. Dynamic changes of lymphocyte subsets in the course of covid-19. Int Arch Allergy Immunol. 2021;182(3):254-62. [DOI:10.1159/000514202] [PMID] [PMCID]
56. Singh S, Sharma A, Arora SK. High producer haplotype (CAG) of -863C/A, -308G/A and -238G/A polymorphisms in the promoter region of TNF-α gene associate with enhanced apoptosis of lymphocytes in HIV-1 subtype C infected individuals from north India. Plos One. 2014;9(5):98020. [DOI:10.1371/journal.pone.0098020] [PMID] [PMCID]
57. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α. J Immunol. 2002;169(8):4288-97. [DOI:10.4049/jimmunol.169.8.4288] [PMID]
58. Aggarwal S, Gollapudi S, Gupta S. Increased TNF-α-induced apoptosis in lymphocytes from aged humans: Changes in TNF-α receptor expression and activation of caspases. J Immunol. 1999;162(4):2154-61. [link]
59. Chan JFW, Zhang AJ, Yuan S, Poon VKM, Chan CCS, Lee ACY, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: Implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71(9):2428-46. [DOI:10.1093/cid/ciaa325] [PMID] [PMCID]
60. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145-8. [DOI:10.1016/j.cca.2020.03.022] [PMID] [PMCID]
61. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-8. [DOI:10.1007/s00277-020-04019-0] [PMID] [PMCID]
62. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40. [DOI:10.1182/blood.2020006000] [PMID] [PMCID]
63. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: A retrospective study. Chinese Med J. 2020;133(11):1261-7. [DOI:10.1097/CM9.0000000000000824] [PMID] [PMCID]
64. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3]
65. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-90. [DOI:10.1080/22221751.2020.1741327] [PMID] [PMCID]
66. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. [DOI:10.1111/jth.14768] [PMID] [PMCID]
67. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):438-40. [DOI:10.1016/S2352-3026(20)30145-9]
68. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401-9. [DOI:10.1093/intimm/dxx031] [PMID] [PMCID]
69. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:1295. [DOI:10.1136/bmj.m1295] [PMID]
70. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. [DOI:10.1172/JCI137244] [PMID] [PMCID]
71. Zhang H, Wang X, Fu Z, Luo M, Zhang Z, Zhang K, et al. Potential factors for prediction of disease severity of COVID-19 patients. MedRxiv. 2020 Mar:1-26. [DOI:10.1101/2020.03.20.20039818]
72. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75(7):1730-41. [DOI:10.1111/all.14238] [PMID]
73. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, Chin. Clin Microbiol Infect. 2020;26(6):767-72. [DOI:10.1016/j.cmi.2020.04.012] [PMID] [PMCID]
74. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):18. [DOI:10.1186/s12941-020-00362-2] [PMID] [PMCID]
75. Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A tool for early prediction of severe coronavirus disease 2019 (COVID-19): A multicenter study using the risk nomogram in Wuhan and Guangdong, China. Clin Infect Dis. 2020;71(15):833-40. [DOI:10.1093/cid/ciaa443] [PMID] [PMCID]
76. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8. [DOI:10.1515/cclm-2020-0369] [PMID]
77. Thomas J, Pociute A, Kevalas R, Malinauskas M, Jankauskaite L. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: A literature review. Ital J Pediatr. 2020;46(1):4. [DOI:10.1186/s13052-020-0770-3] [PMID] [PMCID]
78. Gulhar R, Ashraf MA, Jialal I. Physiology, acute phase reactants. StatPearls; 2018. [link]
79. Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: A systematic review and meta-analysis. Crit Care. 2020;24(1):255. [DOI:10.1186/s13054-020-02995-3] [PMID] [PMCID]
80. Violi F, Cangemi R, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, et al. Is albumin predictor of mortality in COVID-19. Antioxid Redox Signal. 2021;35(2):139-42. [DOI:10.1089/ars.2020.8142] [PMID]
81. Mair J, Lindahl B, Hammarsten O, Muller C, Giannitsis E, Huber K, et al. How is cardiac troponin released from injured myocardium. Eur Heart J Acute Cardiovasc Care. 2018;7(6):553-60. [DOI:10.1177/2048872617748553] [PMID]
82. Majure DT, Gruberg L, Saba SG, Kvasnovsky C, Hirsch JS, Jauhar R, et al. Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury. Am J Cardiol. 2021;138:100-6. [DOI:10.1016/j.amjcard.2020.09.060] [PMID] [PMCID]
83. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8. [DOI:10.1016/j.jaci.2020.04.006] [PMID] [PMCID]
84. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020;311:116-21. [DOI:10.1016/j.ijcard.2020.03.087] [PMID] [PMCID]
85. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. [DOI:10.1016/j.kint.2020.03.005] [PMID] [PMCID]
86. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID‐19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;40(9):2095-103. [DOI:10.1111/liv.14455] [PMID]
87. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529-30. [DOI:10.1016/S2468-1253(20)30084-4]
88. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. [DOI:10.1016/S2468-1253(20)30057-1]
89. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect. 2020;53(3):368-70. [DOI:10.1016/j.jmii.2020.03.005] [PMID] [PMCID]
90. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. [DOI:10.1016/S0140-6736(20)30628-0]
91. European society of intensive care medicine. Important announcement of new SSC guidelines-COVID-19 [Internet]. Unknown Publisher City. European Society of Intensive Care Medicine; 2020 [cited: Unknown]. Available from: https://www.esicm.org/ssc-covid19-guidelines/. [link]
92. Shang Y, Xu C, Jiang F, Huang R, Li Y, Zhou Y, et al. Clinical characteristics and changes of chest CT features in 307 patients with common COVID-19 pneumonia infected SARS-CoV-2: A multicenter study in Jiangsu, China. Int J Infect Dis. 2020;96:157-62. [DOI:10.1016/j.ijid.2020.05.006] [PMID] [PMCID]
93. Kasraeian M, Zare M, Vafaei H, Asadi N, Faraji A, Bazrafshan K, et al. COVID-19 pneumonia and pregnancy: A systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2020 May:1-8. [DOI:10.1080/14767058.2020.1763952] [PMID]
94. Vakili S, Savardashtaki A, Jamalnia S, Tabrizi R, Nematollahi MH, Jafarinia M, et al. Laboratory findings of COVID-19 infection are conflicting in different age groups and pregnant women: A literature review. Arch Med Res. 2020;51(7):603-7. [DOI:10.1016/j.arcmed.2020.06.007] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |